Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Antiandrogens Stories

2011-04-28 13:40:00

SILVER SPRING, Md., April 28, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Zytiga (abiraterone acetate) in combination with prednisone (a steroid) to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) In prostate cancer, the male sex hormone testosterone stimulates prostate tumors to grow. Drugs or surgery are...

2011-03-07 21:38:28

URMC Research Confirms Possible Use of Drug for Painful Fibroids Research continues to show that the controversial abortion drug mifepristone might have another use, as a therapeutic option besides hysterectomy for women who suffer from severe symptoms associated with uterine fibroids. The University of Rochester Medical Center in 2004 began investigating mifepristone, in a class of drugs known as progesterone receptor modulators (PRMs), to treat fibroids, which affect roughly half of all...

2010-11-29 15:05:00

SAN FRANCISCO and TOKYO, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has...

2010-10-12 17:53:40

Phase III results Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm. "This is a major step forward in prostate cancer therapeutics," said Dr Johann de Bono from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in London, who presented the study results at the 35th...

2010-10-01 16:08:00

WASHINGTON, Oct. 1 /PRNewswire-USNewswire/ -- U.S. Centers for Disease Control and Prevention officials have disclosed that two mifepristone (RU-486)-induced deaths occurred in the past two years, bringing the total number of reported death related to RU-486 to 12. This announcement comes almost 10 years to the date after the Food and Drug Administration (FDA) approved the abortion drug, deeming it a major advancement for women's health and safe for public use. (Logo:...

2010-09-29 07:00:00

SAN FRANCISCO and TOKYO, Sept. 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received...

2010-09-09 17:05:00

LOS ANGELES, Sept. 9 /PRNewswire/ -- Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel. Study...

2010-07-07 13:31:11

In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread. However, advanced prostate cancers are often androgen-independent, meaning that androgen-blocking therapies are ineffective. Scientists aren't sure how this shift occurs as prostate cancer advances. One idea is that prostate cancer...

2010-06-01 15:30:00

SAN FRANCISCO, June 1 /PRNewswire/ -- FIRMAGON® (degarelix for injection) resulted in fast, long-term suppression of testosterone in prostate cancer patients, without an initial testosterone surge or microsurge, and rapidly reduced prostate-specific antigen (PSA) levels, according to a review of data presented here today at the AUA 2010 annual meeting by Dr. Judd Moul, Chief of the Division of Urology at Duke University Health Science Center. Dr. Moul was joined at the...

2010-06-01 08:00:00

SAN FRANCISCO, June 1 /PRNewswire/ -- Prostate cancer patients on leuprolide who were offered to continue on FIRMAGON® (degarelix for injection) after one year of treatment reduced prostate specific antigen (PSA) recurrence, according to results of a Phase III extension study(1) presented here at the American Urological Association 2010 meeting. PSA is commonly used in monitoring prostate cancer patients' treatment response, and a high PSA number may indicate prostate...